David R. Margrave - Oct 29, 2021 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Chief Financial Officer
Signature
/s/ David R. Margrave
Stock symbol
LTRN
Transactions as of
Oct 29, 2021
Transactions value $
$0
Form type
4
Date filed
11/2/2021, 04:05 PM
Next filing
Jul 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Award $0 +26.1K $0.00 26.1K Oct 29, 2021 Common Stock 26.1K $10.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon November 29, 2021.